A 2025 proof-of-concept case report described the neoadjuvant administration of a triplet immune checkpoint blockade (nivolumab, ipilimumab, and relatlimab targeting PD-1, CTLA-4, and LAG-3, respectively) in a single patient with newly diagnosed IDH-wildtype, MGMT-unmethylated glioblastoma [87]. Here, IDH1 is linked to glioblastoma.